Insights

Gene Therapy Demand Brammer Bio operates as a viral vector CDMO for gene-modified cell therapies and in vivo gene therapies, with end-to-end services from early-phase to commercial manufacturing. This indicates strong alignment with large pharma and biotech clients seeking scalable viral vector manufacturing capabilities.

Geographic Footprint Operations span Florida for Phase I/II development and Massachusetts for commercial manufacturing, suggesting opportunities for clients seeking phased manufacturing strategies and potential collaboration across multiple regional hubs.

Strategic Partnerships Historically active in partnerships and acquisitions within the CDMO space, including notable industry consolidations, signaling openness to collaboration or integration with partners for capacity, technology, or process development advantages.

Scale and CapacityBuild Recent investments in quality control laboratories and process development capabilities imply a focus on expanding manufacturing readiness, QC, and analytical development services—areas ripe for cross-sell to clients needing enhanced control and compliance support.

Customer Focus Specialization in providing clinical and commercial viral vector supply, regulatory support, and end-to-end development indicates a full-service value proposition suitable for clients seeking a single-CDMO partner to accelerate time-to-market and reduce vendor fragmentation.

Similar companies to Brammer Bio

Brammer Bio Tech Stack

Brammer Bio uses 8 technology products and services including AutoCAD, SAP, Bluebeam, and more. Explore Brammer Bio's tech stack below.

  • Cad & Graphics
  • Customer Relationship Management
  • Document Management Systems
  • Enterprise
  • Human Resource Management System
  • Zepto
    Javascript Libraries
  • Microsoft Windows
    Operating Systems
  • Virtualisation Software

Media & News

Brammer Bio's Email Address Formats

Brammer Bio uses at least 4 email formats:
Brammer Bio Email FormatsExamplePercentage
First.Last@brammerbio.comJohn.Doe@brammerbio.com
94%
FirstLast@brammerbio.comJohnDoe@brammerbio.com
3%
Last.First@brammerbio.comDoe.John@brammerbio.com
1%
Last@brammerbio.comDoe@brammerbio.com
2%

Frequently Asked Questions

What is Brammer Bio's official website and social media links?

Minus sign iconPlus sign icon
Brammer Bio's official website is brammerbio.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does Brammer Bio generate?

Minus sign iconPlus sign icon
As of October 2026, Brammer Bio's annual revenue is estimated to be $10M - $25M.

What is Brammer Bio's SIC code and NAICS code?

Minus sign iconPlus sign icon
Brammer Bio's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Brammer Bio have currently?

Minus sign iconPlus sign icon
As of October 2026, Brammer Bio has approximately 46 employees across 1 continents, including North America. Key team members include Chief Executive Officer: M. B., Chief Operations Officer: C. C. and Principal Owner: J. M. Explore Brammer Bio's employee directory with LeadIQ.

What industry does Brammer Bio belong to?

Minus sign iconPlus sign icon
Brammer Bio operates in the Biotechnology Research industry.

What technology does Brammer Bio use?

Minus sign iconPlus sign icon
Brammer Bio's tech stack includes AutoCAD, SAP, Bluebeam, Oracle ERP, ADP, Zepto, Microsoft Windows and VMware.

What is Brammer Bio's email format?

Minus sign iconPlus sign icon
Brammer Bio's email format typically follows the pattern of First.Last@brammerbio.com. Find more Brammer Bio email formats with LeadIQ.

When was Brammer Bio founded?

Minus sign iconPlus sign icon
Brammer Bio was founded in 2016.
Brammer Bio logo

Brammer Bio

Biotechnology ResearchMassachusetts, United States11-50 Employees

Brammer Bio is a biotechnology-focused contract development and manufacturing organization specializing in viral vectors for gene therapies. It provides end-to-end services across the development and manufacturing spectrum, including clinical and commercial supply for both in vivo gene therapies and cells modified ex vivo, along with process and analytical development and regulatory support. The company conducts Phase I/II work in Florida and scales to commercial production in Massachusetts, and is based in Cambridge, Massachusetts. 

Its client base includes large pharmaceutical and biotechnology companies seeking to accelerate the delivery of novel gene therapies, supported by Brammer's dedicated team focused on gene therapy needs. The leadership team comprises President and CEO Mark Bamforth, Chief Scientific Officer Dr. Richard Snyder, and Chief Operating Officer Christopher Murphy.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2016
Employees
11-50

Section iconFunding & Financials

  • $10M - $25M

    Brammer Bio's revenue is estimated to be in the range of $10M - $25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.